Supplementary Table S1 from BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail

Antibodies used in this study</p

Supplementary Table S2 from BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail

Correlation between BRD4 protein levels in gastric cancer tissues and related clinicopathologic parameters</p

Supplementary Materials from BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail

Suppl Materials and Methods; Suppl Fig. S1: Elevated expression of BRD4 in gastric cancer tissues correlates with inferior prognosis; Suppl Fig. S2: Depletion of BRD4 inhibits proliferation and tumorigenicity of gastric cancer cells; Suppl Fig. S3: Depletion of BRD4 inhibits invasiveness and peritoneal metastasis of gastric cancer cells; Suppl Fig. S4: BRD4 up-regulates Snail at post-translational levels in gastric cancer cells; Suppl Fig. S5: BRD4 fails to stabilize acetylation-deficient Snail in cells; Suppl Fig. S6: BRD4 competes with FBXL14 and β-Trcp1 for binding Snail and suppresses GSK-3β-mediated phosphorylation of Snail; Suppl Fig. S7: BRD4 promotes cell proliferation and colony formation in part through elevating Snail expression; Suppl Fig. S8: Snail expression is inversely correlated with β-Trcp1 and FBXL14 in gastric cancer tissues; Suppl Fig. S9: BRD4 and Snail regulate a shared subset of metastatic genes in gastric cancer cells.</p

Figure S2 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Kaplan-Meier analyses of PFS for patients with normal and elevated ({greater than or equal to}7 pg/ml) baseline IL-6 levels.</p

Figure S3 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Impact of the IL-6 cutoff level on progression-free survival (A) and overall survival (B).</p

Figure S1 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Kaplan-Meier curves for progression-free survival in subgroups.</p

Figure S4 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Dynamics of IL-6 levels in the two treatment groups at different time points (A) and comparison of the IL-6 levels between the two arms at each time point (B).</p